Regulus Therapeutics Inc., a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, named Preston Klassen president and head of research and development, and Curtis Monnig, vice president of CMC. Klassen brings over 20 years of experience in leadership roles in both large and small biopharmaceutical companies. He is an established nephrologist who brings years of experience in leadership, medical affairs, and research and development ac...